An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics Of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
Latest Information Update: 18 Aug 2021
At a glance
- Drugs Polatuzumab vedotin (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 16 Mar 2019 Results ethnic sensitivity assessment by using data from two phase I and a phase II studies presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 07 Jun 2016 Results comparing two phase I studies (JO29138 and DCS4968g ; n=7) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 03 Apr 2014 Status changed from active, no longer recruiting to completed.